Vanguard Group
HRMY icon

Vanguard Group’s Harmony Biosciences HRMY Stock Holding History

Vanguard Group’s Portfolio HRMY Stock Details HRMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$180M Sell
4,813,357
-283,819
-6% -$9.33M ﹤0.01% 1599
2025
Q3 		$140M Sell
5,097,176
-13,604
-0.3% -$469K ﹤0.01% 1707
2025
Q2 		$162M Buy
5,110,780
+411,427
+9% +$13.2M ﹤0.01% 1610
2025
Q1 		$156M Sell
4,699,353
-34,256
-0.7% -$1.23M ﹤0.01% 1585
2024
Q4 		$163M Buy
4,733,609
+1,262,362
+36% +$43.4M ﹤0.01% 1635
2024
Q3 		$139M Sell
3,471,247
-48,140
-1% -$1.69M ﹤0.01% 1727
2024
Q2 		$106M Sell
3,519,387
-108,838
-3% -$3.27M ﹤0.01% 1805
2024
Q1 		$122M Sell
3,628,225
-46,539
-1% -$1.49M ﹤0.01% 1763
2023
Q4 		$119M Sell
3,674,764
-9,388
-0.3% -$262K ﹤0.01% 1774
2023
Q3 		$121M Buy
3,684,152
+88,295
+2% +$3.07M ﹤0.01% 1703
2023
Q2 		$127M Buy
3,595,857
+60,572
+2% +$2.09M ﹤0.01% 1725
2023
Q1 		$115M Buy
3,535,285
+280,644
+9% +$12.8M ﹤0.01% 1759
2022
Q4 		$179M Buy
3,254,641
+251,185
+8% +$13.8M ﹤0.01% 1491
2022
Q3 		$133M Buy
3,003,456
+38,958
+1% +$1.9M ﹤0.01% 1624
2022
Q2 		$145M Buy
2,964,498
+261,985
+10% +$11.8M ﹤0.01% 1615
2022
Q1 		$131M Buy
2,702,513
+43,428
+2% +$1.77M ﹤0.01% 1789
2021
Q4 		$113M Sell
2,659,085
-440,856
-14% -$17.6M ﹤0.01% 1919
2021
Q3 		$119M Buy
3,099,941
+1,938,066
+167% +$62.4M ﹤0.01% 1897
2021
Q2 		$32.8M Buy
1,161,875
+350,935
+43% +$10.5M ﹤0.01% 2583
2021
Q1 		$26.8M Buy
810,940
+642,758
+382% +$22.5M ﹤0.01% 2626
2020
Q4 		$6.08M Buy
+168,182
New +$6.79M ﹤0.01% 3264

Other funds holding HRMY

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $92.9B AUM 36.98% 1-Year Est. Return

Vanguard Group's HRMY Position: Q4 2025 in Review

Vanguard Group reduced its Harmony Biosciences (HRMY) stake by 5.6% in Q4 2025, selling an estimated $9.33M and leaving 4,813,357 shares worth $180M. The position accounts for ﹤0.01% of the portfolio, ranked #1599.

Vanguard Group first reported a position in HRMY in Q4 2020 and has held it in 21 quarters since. 323 funds tracked by Wall St. Rank hold HRMY as of Q4 2025.

  • Vanguard Group held 4,813,357 shares of Harmony Biosciences worth $180M as of Q4 2025.
  • Vanguard Group sold 283,819 Harmony Biosciences shares in Q4 2025, an estimated $9.33M.
  • Harmony Biosciences made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #1599 holding.
  • Vanguard Group first reported a position in Harmony Biosciences in Q4 2020 and has held it in 21 quarters since.
  • 323 funds tracked by Wall St. Rank held Harmony Biosciences as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.